Entries from India Chemicals Blog tagged with 'CRAMS'
More changes at Jubilant?
Jubilant Organosys appears to be taking one more step in transforming itself into a pharmaceutical company. The company is looking at selling its industrial and performance products division and expects to realise Rs3.0-3.5bn from the sale, says this report in...
Not so fine anymore?
News is slowly trickling in of Indian pharmaceutical and fine chemical companies shutting down facilities that were acquired with great zeal during the 2005-08 overseas acquisition drive. Shasun has decided to shut its facility at Newbie in Scotland and is...
Confident CRAMS
There are a few optimistic companies that are betting on growth in the midst of inflation, rising crude oil prices and a worldwide economic slowdown. Some custom research and manufacturing services (CRAMS) players believe that the pressure on costs will...
Hikal scores in CRAMS
Hikal is busy consolidating its position in the Indian CRAMs (contract research and manufacturing services) space. It recently secured a long-term contract with Bayer CropScience for supply of active ingredients for crop protection chemicals. And now Hikal plans to invest...
Testing times for CRAMS
Business is booming in India’s custom research and manufacturing services (CRAMS) industry thanks to the country's strong process chemistry skills, low operational costs and the availability of a skilled workforce. Frost & Sullivan values the Indian CRAMS market at $890m,...
CRAMs comes with challenges
India’s success in the global custom research and manufacturing services space (CRAMS) is well documented. And the untapped potential is huge especially as western pharmaceutical companies remain under pressure to cut costs. According to one estimate, the global manufacturing outsourcing...
CRAMS: still going strong
Indian companies in the contract research and manufacturing services (CRAMS) domain appear to be doing well as is reflected in the stock market performance of these companies. The list includes Divi’s Laboratories, Dishman Pharmaceuticals & Chemicals, Nicholas Piramal, Shasun Chemicals...
Opportunties in CRAMS
With an estimated annual growth of 25%, the Indian contract research and manufacturing services (CRAMS) sector is attracting global attention. Globally, drugs worth $70 billion would be going off-patent by 2011 and Indian companies providing contract manufacturing services are expected...
Jubilant CRAMS another acquisition
Jubilant Organosys $123m acquisition of US-based Hollister-Stier Labs further consolidates is position in the global custom research and manufacturing (CRAMs) business. Interestingly, Jubilant will not be moving projects to India following the acquisition. In an interview with CNBC, Hari Bhartia,...
Indian chemicals score on CRAMS
Jubiliant Organosys' announcement that it has clinched deals worth $60m from global life science majors reinforces India's growing strength in the custom research and manufacturing services (CRAMS) business. Rising competition and research costs are supporting the CRAMS outsourcing wave and...
Feed Subscription
If you use an RSS reader, you can subscribe to a feed of all future entries tagged 'CRAMS'. [What is this?]
